TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Myocardial stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: MVPA change from baseline to postintervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: neovascularisation maximal diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: need for reoperation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Decreased infectious morbidity
Endpoint domain: Adverse events/effects
Primary endpoint: Fall in diastolic BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Risk scores in high risk group
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increases in plasma PC EPA and DHA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increases in erythrocyte EPA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decreases in plasma PC and erythrocyte linoleic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TT levels after ovulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: biopsy proven acute rejections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Intrauterine adhesions severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Nonfatal reinfarctions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Class III or IV angina
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: in-stent binary restenosis rate at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Response rate to interpersonal psychotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: absence of withdrawal bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: unscheduled bleeding and/or spotting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adenosine phosphate‐mediated platelet aggregation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Hypotension occurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Performance on executive tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Daily executive function problems
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Depression improvement (HAMD-17 change)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HbA1c mean score changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Likelihood of returning to donate
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Endothelial integrity preservation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean time to recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: tumor progression rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Development of PCP
Endpoint domain: Adverse events/effects
Primary endpoint: Transfusion-free survival
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean haemoglobin count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: implant loss
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative pain on days 1 and 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient recommendation of the procedure
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: incision-related blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: cosmetic outcomes
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: satisfaction outcomes
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: free T levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Postoperative analgesic requirement (Diclofenac Na)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 40-km time-trial performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heart-rate recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean platelet count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Area Under the Curve (AUC) for MPA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak Concentration (Cmax) for MPA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of major postoperative complications
Endpoint domain: Adverse events/effects
Primary endpoint: Overall postoperative mortality rates
Endpoint domain: Mortality/survival
Primary endpoint: Polyp regression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: daytime plaque coverage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total therapist time per child
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: EQ-VAS score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient preference for access strategy
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Insulin secretion (AIRg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Glucose tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Improvement in SRT immediate recall (SRT-IR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Unplanned HF readmissions
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Nicotine Metabolism Rate (NMR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in 9HPT time over 120 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of CP of ⩾20% in 9HPT time for both hands
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of more severe 9HPT progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Corrected QT interval (QTc) increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Global akathisia scores increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FEV1 reversibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: MEF75 reversibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Myocardial Infarction (MI) rate
Endpoint domain: Adverse events/effects
Primary endpoint: Stroke rate
Endpoint domain: Adverse events/effects
Primary endpoint: 24-hour fractional excretion of phosphorus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Immediate complete pain-relief rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained pain-relief rates at 12, 24, and 36 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Annual recurrence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interventricular electromechanical delay > 50 ms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intra-LV electromechanical delay > 50 ms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: QRS width > 190 ms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in interpretive errors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Acuity (VA) of 6/12 or better
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiovascular death, myocardial infarction, or ischemia-driven revascularization
Endpoint domain: Mortality/survival
Primary endpoint: Cognitive activation
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Complete clearance of ocular inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptability of restorations for continued use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CTDIvol differences
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Signal to noise ratio (SNR) values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Larger infarct size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in RBANS total score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in RBANS delayed memory score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Mobility rating
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: EQ‐5D Visual Analogue Scale score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 6-month change in office SBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 6-month change in 24-h ambulatory SBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mean pain score 2 h postoperatively during rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma total homocysteine level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: AUC(0‐last) of paclitaxel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C (max) of paclitaxel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: restoration of vision
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-exercise glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Platelet reactivity inhibition (PRI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: V E at 75%, 80%, and 100% of V[spacing dot above]O2max
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: HbSaO2 at V[spacing dot above]O2max
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: microvascular endothelial function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drug-related problems per senior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median prescription cost
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: First-line drug use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participation willingness in future programs
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: sensitivity of B-score system
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: specificity of B-score system
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: savings in unnecessary antibiotic prescription
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Duration of extracorporeal circulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative bleeding rates
Endpoint domain: Adverse events/effects
Primary endpoint: Leg wound infection rates
Endpoint domain: Adverse events/effects
Primary endpoint: Participants' perspective on trauma
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Participants' perspective on their future
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Fluorescein staining
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rose Bengal staining
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic accuracy for high grade cancer detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infarct size at 30 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Severity of stroke (NIHSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean Barthel index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: patient active participation
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Improvement in glabellar lines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events after treatment
Endpoint domain: Adverse events/effects
Primary endpoint: long-term patency of arteriovenous fistulae
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Near vision outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: comfortable wearing time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total wearing time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ocular itch improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean percentage of radiographic DDR%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: toilet voids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: urgency severity/void
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correct incisions made
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Active use of both hands in endoscopic evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Improvement in weaker erections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Increases in hormonal levels (TT, free T, E2, LH, FSH, SHBG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Improvements in lean mass, fat-free mass, and muscle mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IDWG levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: shoulder motor function improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: shoulder pain evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression of CAC scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: time to disease progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Renal vascular resistance (RVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: blood oxygen saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cure rate of hearing recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MACE (myocardial infarction, stroke and cardiac death)
Endpoint domain: Mortality/survival
Primary endpoint: Weight gain after 6 months of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-h area under the curve for insulin (INS-AUC(0-24) (h))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: glucose infusion rates (GIR-AUC(0-24) (h))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in mouth opening (MMO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TCC-related thrombotic dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: number of headache days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in ESS scores
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Excessive daytime sleepiness
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Respiratory disturbance index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of trigger digit after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increasing suicidal ideation
Endpoint domain: Adverse events/effects
Primary endpoint: Serious bleeding events
Endpoint domain: Adverse events/effects
Primary endpoint: Bioequivalence of PK parameters (AUCinf, AUClast, Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intake of servings of fruits, vegetables, and refined grains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: leisure time walking
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: HOMA-insulin resistance (HOMA-IR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Limb volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Angiographic quality scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: loco-regional tumor control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Major Adverse Cardiac Event (MACE)
Endpoint domain: Adverse events/effects
Primary endpoint: Flatulence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Abdominal pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Overall GI function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Distance covered in the 6-min walking test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: double support time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ground reaction force (GRF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fewer outliers in frontal alignment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved tibial slope achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emotional memory enhancement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in signs of photodamage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Average roughness improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: apo A‐1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hemoglobin change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Dilaudid PCA usage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of hematoma and hyperemia areas
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Better border closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: DLQI response
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Treatment efficacy comparison between NSAIDs and paracetamol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total effective vascular compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Cardiovascular death, major coronary event or stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: gains in computer‐presented knowledge items
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: gains in observational helmet measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pattern Electroretinograms (PERGs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Evoked Potentials (VEPs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of child body posture limiting parental book access
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of child closing the book
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of parent pivoting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in HIV-1 RNA at day 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: safety and tolerability of mirabegron
Endpoint domain: Adverse events/effects
Primary endpoint: MACTAR functional scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 5-meter walking test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: episodes of severe hypoglycemia
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of visual field loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes